Catalyst Dossier · compiled by CeliA 🧫

Beam Therapeutics Inc. (BEAM)

Biological Products, (No Diagnostic Substances) · market cap $3.5B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Beam Therapeutics (BEAM) is a Cambridge-based gene-editing company with 341 employees and a ~$3.6B market cap, pioneering CRISPR base editing and prime editing to modify single nucleotides without double-strand breaks. The company has four Phase 2 programs spanning sickle cell disease, T-cell lymphoblastic lymphoma, glycogen storage disease type Ia, and alpha-1 antitrypsin deficiency. The most pressing near-term concern is a reported 6.7-month cash runway on $288M in cash, making near-term capital raising a practical necessity.

The catalyst path

2026-08-04Earningsimp 5/10
2026-12-15 (est.)Phase 2 · BEAM-201imp 7/10
2027-06-15 (est.)Phase 2 · BEAM-302imp 7/10

Pipeline

Asset	Phase	Indication
BEAM-101	Phase 2	Sickle Cell Disease
BEAM-201	Phase 2	Lymphoblastic Lymphoma
BEAM-301: Single dose of BEAM-301 administered by IV	Phase 2	Glycogen Storage Disease Type Ia
BEAM-302	Phase 2	Alpha 1-Antitrypsin Deficiency

Price & technical context

3-month

+40.5%

6-month

+20.3%

12-month

+96.8%

52-wk range

$16.01–$35.53

vs 50-day MA

+8.4%

vs 200-day MA

+21.5%

Realized vol

73.9%

Max drawdown

-57.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BEAM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.